Margetuximab

Metastatic Neoplasm

MacroGenicsmonoclonal_antibodyPhase 3Dormant

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 95/ 100

Competitive context

171 Active assets in the Metastatic Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Eloxatin Ruijin Hospital	Phase 4	BBB
FLUOROURACILUM Ruijin Hospital	Phase 4	BBB
Irinotecan Eli Lilly and Company	Phase 4	BBB
DEXAMETHASONE Janssen Research & Development, LLC	Phase 2	BBB
Atezolizumab UNC Lineberger Comprehensive Cancer Center	Phase 2/3	BB

View all 50 →

Same molecule, other indications

Margetuximab is also rated in:

HER-2 Positive Breast CancerDormant

B

Indicative ·

62 / 100

breast cancerDormant

CCC

Indicative ·

53 / 100

HER2 positive breast carcinomaDormant

CCC

Indicative ·

48 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.